Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Aug 19, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Decoding molecular programs in melanoma brain metastases.

Josefine Radke^1,2,3,4, Elisa Schumann^5,6, Julia Onken^5,7

¹Department of Pathology, University Medicine Greifswald, Greifswald, Germany. josefine.radke@med.uni-greifswald.de.

Nature Communications

|November 26, 2022

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: <sup>1</sup>H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis.

Scientific reports·2026

Same author

S1 guideline sweat gland carcinoma.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026

Same author

[Surgical management of spinal metastases].

Orthopadie (Heidelberg, Germany)·2026

Same author

Impact of infratentorial location on survival after surgical resection of brain metastases: a multicenter retrospective study.

Neuro-oncology advances·2026

Same author

Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients-A Multicenter Retrospective Cohort Study.

International journal of cancer·2026

Summary

This summary is machine-generated.

Melanoma brain metastases (MBM) show distinct molecular subtypes. A switch from E-cadherin (Ecad) to NGFR expression indicates progression and potential therapy resistance in melanoma patients.

Area of Science:

Oncology
Molecular Biology
Genomics

Background:

Melanoma brain metastases (MBM) exhibit variable responses to treatment, complicating prognosis.
The underlying mechanisms driving therapeutic response and disease progression in MBM remain largely unknown.

Purpose of the Study:

To investigate the molecular programs controlling progressive intracranial disease in MBM.
To identify biomarkers predicting therapy response and prognosis in MBM.

Main Methods:

Multi-omics approach integrating targeted sequencing (TargetSeq).
Analysis of E-cadherin (Ecad) and NGFR expression, BRAF mutation status, and immune cell infiltration.
Global methylome profiling.

Main Results:

More Related Videos

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Experiment Videos

Last Updated: Aug 19, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

MBM tumors were classified into proliferative/pigmented and invasive/stem-like/therapy-resistant subtypes based on Ecad, NGFR, BRAF mutation, and immune infiltration.
A switch from Ecad-associated to NGFR-associated programs was observed during progression in MAPK inhibitor-naive and refractory MBM.
NGFR-associated programs influence cell migration and proliferation via SOX4.
46 differentially methylated regions distinguished BRAF-mutant from BRAF wildtype MBM.

Conclusions:

E-cadherin (Ecad) and NGFR expression effectively subclassify MBM.
The Ecad-to-NGFR phenotype switch is a critical process linked to drug response and intracranial progression in melanoma patients.